{"filing":{"accession_number":"0001326110-26-000077","cik":"0001326110","ticker":"IBRX","company_name":"ImmunityBio, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"ibrx-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/ibrx-20260804.htm"},"events":[{"id":23934,"run_id":21647,"accession_number":"0001326110-26-000077","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"ImmunityBio disclosed quarterly and first-half 2026 financial results via press release attached as Exhibit 99.1, including net product revenue of $50.7 million (Q2 2026, up 92% YoY) and $94.8 million (H1 2026, up 121% YoY), along with detailed consolidated statements of operations, balance sheet data, and cash flow summaries. This is a standard earnings release disclosure under Item 2.02.","company_name":"ImmunityBio, Inc.","ticker":"IBRX","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24295,"accession_number":"0001326110-26-000077","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"ImmunityBio disclosed quarterly and first-half 2026 financial results via press release attached as Exhibit 99.1, including net product revenue of $50.7 million (Q2 2026, up 92% YoY) and $94.8 million (H1 2026, up 121% YoY), along with detailed consolidated statements of operations, balance sheet data, and cash flow summaries. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:32:08.972323+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24295,"accession_number":"0001326110-26-000077","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"ImmunityBio disclosed quarterly and first-half 2026 financial results via press release attached as Exhibit 99.1, including net product revenue of $50.7 million (Q2 2026, up 92% YoY) and $94.8 million (H1 2026, up 121% YoY), along with detailed consolidated statements of operations, balance sheet data, and cash flow summaries. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:32:08.972323+00:00","company_name":"ImmunityBio, Inc.","ticker":"IBRX","filing_date":"2026-08-04"}]}